POLYSTYRENELOOP
3.6.2021 19:01:08 CEST | Business Wire | Press release
A new recycling plant in the Netherlands will recycle expanded polystyrene (EPS) demolition waste and also handle a legacy additive.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005924/en/
The PolyStyreneLoop recycling plant in Terneuzen, Netherlands, is scheduled to open on the 16th of June. The plant was built to prove the technical and economic feasibility of a large-scale, closed-loop solution for the recycling of EPS waste.
The PolyStyreneLoop facility will recycle EPS insulation using a physical recycling process based on the CreaSolv® Technology. This technology will turn EPS foam demolition waste from building and construction insulation (B&C) from the Netherlands, Germany and other countries into new high quality raw material. All kinds of impurities, such as cement or other construction residues, as well as the legacy additive HBCD, will be safely removed and valuable bromine recovered.
“This plant showcases how the EPS industry is always looking for ways to boost its recycling capabilities,” said Lein Tange, Co-Director of PolyStyreneLoop. “The purpose of this plant is to pave the way for the construction of similar EPS recycling plants in the rest of Europe.”
The legal structure of the plant, which benefited from a European Union LIFE programme grant, was also unique. It has been built by the PolyStyreneLoop Cooperative, a Dutch non-profit organisation whose members comprise more than 70 industry representatives from the whole polystyrene foam value chain.
The Terneuzen plant will have the capacity to recycle 3,300 metric tonnes of polystyrene foam demolition waste coming from B&C per year, validating the technical, economic, and environmental viability of a new recycling process in which polystyrene foams containing HBCD can be fully integrated in the circular economy rather than being lost from circularity.
“It’s a real plus that the plant can not only take care of current recycling waste but also legacy recycling waste,” said Jan Noordegraaf, co-director of the plant. “Moreover, we can do this with about the same energy input as mechanical recycling and the energy we use comes solely from windmills.”
The PSLoop plant will demonstrate the possibility of infinite recycling of EPS B&C waste. Later, it will also recycle extruded polystyrene, or XPS, also known as StyrofoamTM .
EPS is a lightweight foam composed of 98% air and 2% technology with outstanding protective and thermal insulation properties. In addition to building and road construction uses, it is widely used in packaging to protect everything from heavy white goods to sensitive electronics, fresh fruit and vegetables, vaccines and even bees.
About PolyStyreneLoop
PolyStyreneLoop is a cooperative representing more than 70 companies from the polystyrene foam value chain. Its members include includes polystyrene raw material producers, foam manufacturers, additives suppliers, foam converters and recyclers as well as EUMEPS, the association and voice of European Manufacturers of Expanded Polystyrene.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005924/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
